Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 24;14:176. doi: 10.1186/s13041-021-00886-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — Somatic mutations of primary lesions cannot differentiate patients with and without CNS metastases. A Genetic profiles of primary lung lesions of patients with brain metastasis (n = 18), leptomeningeal metastasis (n = 11) or without CNS metastases (n = 27) as annotated below. Tissue DNA from four patients without CNS metastasis failed quality control and were excluded from this analysis. Different colors denote different mutation types. The top bars summarize the number of mutations detected from each patient. The left side of the oncoprint indicates the percentage of patients with mutations in the genes indicated on the right side. The side bars summarize the total number of mutations detected and the distribution of mutation types per gene. B Rate of detection for the indicated genes. *P < 0.05. CNS central nervous system, BM brain metastasis, LM leptomeningeal metastasis, no CNS metastases, patients who never developed CNS metastases before their cancer-related death; *P = 0.031 KEAP1 detected in patients with BM vs. those with no CNS metastases. Analyzed by Fisher’s exact test